The epidemiology and etiology of invasive fungal infections have changed over recent decades. Mold infections are more frequently encountered in association with increasing numbers of immunocompromised patients, and molds other than Aspergillus fumigatus, including species not previously recognized as pathogens, have emerged [1, 2]. The appearance of organisms, such as the Fusarium species and the Zygomycetes, with variable sus¬ceptibilities to conventional antifungal agents underscores the importance of correct identification [3].